Article Text

Download PDFPDF
Advances in Clinical Research in Gynecologic Radiation Oncology: An RTOG Symposium
  1. David Gaffney, MD, PhD*,
  2. Arno Mundt, MD,
  3. Julie Schwarz, MD, PhD and
  4. Patricia Eifel, MD§
  1. *Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, Salt Lake City, UT;
  2. Department of Radiation Oncology, University of California San Diego, San Diego, CA;
  3. Department of Radiation Oncology, Washington University School of Medicine, St. Louis, MO; and
  4. §Department of Radiation Oncology, M. D. Anderson Cancer Center, Houston, TX.
  1. Address correspondence and reprint requests to David Gaffney, MD, PhD, Department of Radiation Oncology, Huntsman Cancer Hospital, University of Utah, 1950 Circle of Hope, Rm 1570, Salt Lake City, UT. E-mail: david.gaffney@hci.utah.edu.

Abstract

Abstract There have been inexorable improvements in gynecologic radiation oncology through technologically advances, 3-dimensional imaging, and clinical research. Investment in these 3 critical areas has improved, and will continue to improve, the lives of patients with gynecologic cancer. Advanced technology delivery in gynecologic radiation oncology is challenging owing to the following: (1) setup difficulties, (2) managing considerable internal organ motion, and (3) responding to tumor volume reduction during treatment. Image guidance is a potential route to solve these problems and improve delivery to tumor and sparing organs at risk. Imaging with positron emission tomography–computed tomography and magnetic resonance imaging are contributing significantly to improved accuracy in diagnosis, treatment, and follow-up in cancer of the cervix. Functional imaging by exploiting tumor biology may improve prognosis and treatment. Clinical trials have been the greatest mechanism to improve and establish standards of care in women with vulvar, endometrial, and cervical cancer. There have been multiple technological advances and practice changing trials within the past several decades. Many important questions remain in optimizing care for women with gynecologic malignancies. The performance of clinical trials will be advanced with the use of consistent language (ie, similar staging system and criteria), eligibility criteria that fit the research question, end points that matter, adequate statistical power, complete follow-up, and prompt publication of mature results.

  • Radiation
  • Gynecology
  • Imaging
  • PET/CT
  • Trials

Statistics from Altmetric.com

Footnotes

  • Conflict of interest statement: Dr. Mundt reports 2 Varian-sponsored research grants, a master research agreement with Varian, and participation in their speaker bureau. There are no other potential conflicts to report.

  • Copyright notification: All 3 tables are used with permission from previous publications. We have written notification of permission and will provide it when necessary.

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.